Expertise in
26
conditions

Dr. Ahad A. Sadiq

Hematology
Fort Wayne Medical Oncology And Hematology Inc
2514 E DuPont Rd Ste 100, 
Fort Wayne, IN 
Accepting New Patients
Expertise in
26
conditions
Fort Wayne Medical Oncology And Hematology Inc
2514 E DuPont Rd Ste 100, 
Fort Wayne, IN 

Overview

Ahad Sadiq is a Hematologist practicing medicine in Fort Wayne, Indiana.

Dr. Sadiq is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Hemolytic Anemia, Hemolytic Crisis, Congenital Hemolytic Anemia, Tissue Biopsy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 5 clinical trials. Dr. Sadiq is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MN

Hospital Affiliations

Lutheran Hospital Of Indiana
Kosciusko Community Hospital
Parkview Regional Medical Center
Marion General Hospital
St Joseph Health System, LLC

Languages Spoken

English
Hindi
Urdu

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Fort Wayne Medical Oncology and Hematology Inc
2514 E DuPont Rd Ste 100, Fort Wayne, IN 46825

Additional Areas of Focus

Dr. Sadiq has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Study Phase: Phase 3
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug, Other
Study Phase: Phase 1
View 4 Less Clinical Trials

13 Total Publications

Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer.
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer.
Journal: Targeted oncology
Published: February 02, 2025
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Fort Wayne Medical Oncology And Hematology Inc

2514 E DuPont Rd Ste 100, 
Fort Wayne, IN 
 (0.1 miles away)
260-484-8830
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Yasolatha Nalamolu is a Hematologist practicing medicine in Fort Wayne, Indiana. Dr. Nalamolu is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Myelodysplastic Syndrome (MDS). Dr. Nalamolu is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Fort Wayne Medical Oncology And Hematology Inc

2514 E DuPont Rd Ste 100, 
Fort Wayne, IN 
 (0.1 miles away)
260-484-8833
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients

Praveen Kollipara is a Hematologist practicing medicine in Fort Wayne, Indiana. Dr. Kollipara is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Multiple Myeloma, and Bone Marrow Aspiration. Dr. Kollipara is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Fort Wayne Medical Oncology And Hematology Inc

2514 E DuPont Rd Ste 100, 
Fort Wayne, IN 
 (0.1 miles away)
260-484-8830
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ryan Gonzales is a Hematologist practicing medicine in Fort Wayne, Indiana. Dr. Gonzales is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Myelodysplastic Syndrome (MDS), Thrombocytopenia, and Bone Marrow Aspiration. Dr. Gonzales is currently accepting new patients.

Frequently Asked Questions about Dr. Ahad A. Sadiq

How do I make an appointment with Dr. Ahad A. Sadiq?

You can book an appointment with Dr. Ahad A. Sadiq by calling their office at 260-484-8830. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ahad A. Sadiq a top-rated expert for Hemolytic Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ahad A. Sadiq is classified as an Distinguished expert for Hemolytic Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ahad A. Sadiq specialize in?

While Dr. Ahad A. Sadiq is a Hematology, they have specific expertise in Hemolytic Anemia, Hemolytic Crisis, and Congenital Hemolytic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ahad A. Sadiq participate in research or clinical trials?

Yes. Dr. Ahad A. Sadiq has published 13 articles and abstracts on conditions like Hemolytic Anemia. You can view a list of Dr. Ahad A. Sadiq's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ahad A. Sadiq accept my insurance?

Dr. Ahad A. Sadiq accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 260-484-8830 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sadiq's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 64 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile